UG

Zacks Research Daily Highlights: The article features research reports on 16 major stocks, including Broadcom, Oracle, and Cisco, along with a unique focus on micro-cap stock United-Guardian. The reports are selected from around 70 published by the Zacks analyst team.

Broadcom's Performance: Broadcom has shown strong growth, particularly in AI semiconductors, but faces challenges with contracting gross margins and high debt levels.

Oracle's Growth: Oracle reported a 12% year-over-year revenue increase, driven by cloud services, and expects significant capital expenditures for infrastructure expansion.

Cisco's Business Model Shift: Cisco has transitioned to a subscription-based revenue model, enhancing its portfolio through acquisitions, but is experiencing sluggish sales in its networking segment due to competition and demand issues.

Stock Performance: FONAR Corporation's stock has gained 5% over the past three months, outperforming its industry and sector, but underperforming the S&P 500. Recent developments include a proposal to take the company private and strong third-quarter fiscal results, despite disappointing product sales.

Business Strengths: FONAR's unique Upright MRI technology offers whole-body imaging in various positions, setting it apart in a competitive market. The company benefits from a stable financial structure with minimal debt and a reliable revenue stream from its Health Management Company of America subsidiary.

Challenges and Risks: The company faces challenges such as reliance on no-fault and personal injury claims, which can lead to cash flow issues, and rising operating expenses that have impacted profit margins.

Investment Outlook: FONAR's stock is currently valued lower than the industry average, suggesting potential for growth. Existing investors are advised to hold, while new investors may find opportunities in the stock's upward trend and core growth prospects.

Sales Performance: United-Guardian reported a significant decline in cosmetic ingredient sales due to distributor inventory issues, leading to a 16.3% year-over-year drop in GAAP revenue, while pharmaceutical and medical lubricant segments showed growth.

Future Outlook: The company did not provide financial guidance for the second half of 2025, citing uncertainty about the recovery of cosmetic sales, but expressed hope that resolving distributor inventory issues could improve performance.